William L. Bigbee, PhD
Professor of Pathology
Dr. Bigbee is a member of the University of Pittsburgh Cancer Institute. Dr Bigbee provides departmental research expertise in the areas of cancer biomarkers and mass spectrometry based proteomics methods.
University of Pittsburgh Cancer Institute
Magee-Womens Research Institute
204 Craft Avenue
Pittsburgh, PA 15213
Office Telephone: 412-641-7555
- BS - University of California, Berkeley, 1967
- PhD - University of Oregon, Institute of Molecular Biochemistry, 1974
Specialties:Cancer biomarkers, lung cancer, proteomics
Reserach ExpertiseDr. Bigbee's interests, research activities, and cumulative expertise are focused on the discovery, development and validation of cancer early detection and diagnostic molecular markers for application in translational and clinical research studies. To facilitate this research, Dr. Bigbee maintains University of Pittsburgh Cancer Institute (UPCI) programmatic appointments in the Cancer Epidemiology, and Lung Cancer Programs. Dr. Bigbee's NCI-funded and related research activities include the newly-renewed UPCI SPORE in Lung Cancer in 2011 as Co-Leader of the SPORE Research Project 3 entitled “Lung Cancer Risk Prediction in the Pittsburgh Lung Screening Study”. Dr. Bigbee also receives other collaborative grant funding to develop the use of proteomics technologies for protein expression profiling analysis and biomarker discovery for early detection/diagnosis of breast, esophageal, and lung cancer.
Selected PublicationsView Dr. Bigbee's publications on PubMed
Mehan MR, Williams SA, Siegfried JM, Bigbee WL, Weissfeld JL, Wilson DO, Pass HI, Rom WN, Muley T, Meister M, Franklin W, Miller YE, Brody EN, Ostroff RM (2014) Validation of a blood protein signature for non-small cell lung cancer. Clinical Proteomics 11:32.
Zaidi AH, Gopalakrishnan V, Kasi PM, Zeng X, Malhotra U, Balasubramanian J, Visweswaran S, Sun M, Flint MS, Davison JM, Hood BL, Conrads TP, Bergman JJ, Bigbee WL, Jobe BA (2015) Evaluation of a 4-protein serum biomarker panel – biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP) – for the detection of esophageal adenocarcinoma. Cancer (in press)